Benralizumab for Asthma

This trial examines how well benralizumab, a medication for severe eosinophilic asthma, controls asthma symptoms. Researchers will assess its effectiveness by monitoring inhaler use with special electronic devices. Participants will switch to a study-provided rescue inhaler and document their medication use with photos. Ideal candidates have experienced severe asthma for at least a year, currently use benralizumab, and are willing to use the study's inhalers. As a Phase 4 trial, this study involves an FDA-approved treatment and aims to understand how benralizumab benefits more patients.

Research has shown that benralizumab is generally safe and well-tolerated for people with severe asthma. Several studies found no new safety concerns, and patients from various backgrounds received it well. One study reported that 12.7% of patients experienced mild side effects, while serious side effects were rare, occurring in about 13% of cases. Serious infections were even less common, occurring in 3.8% of cases.

Benralizumab also appears to help reduce asthma attacks. Some studies reported a significant decrease in the number of asthma attacks, which is promising for its long-term use.

Unlike the standard treatments for asthma, which typically involve inhaled corticosteroids and bronchodilators, benralizumab offers a unique approach by specifically targeting and depleting eosinophils, a type of white blood cell involved in inflammation. This mechanism makes benralizumab particularly promising for patients with eosinophilic asthma, as it directly reduces the source of inflammation rather than just addressing symptoms. Researchers are excited about benralizumab because it can potentially lead to more effective and long-term control of asthma symptoms, reducing the need for frequent use of relief inhalers.

Studies have shown that benralizumab can greatly reduce asthma flare-ups. Specifically, patients experienced a 49% to 60% reduction in flare-up rates after 12 weeks of treatment. Benralizumab targets and reduces eosinophils, a type of white blood cell that can worsen asthma symptoms. This treatment is already approved for severe asthma and has proven effective in managing the condition. Additionally, research has shown that the budesonide-albuterol inhaler, called AirSupra, lowers the risk of severe asthma attacks by 27%. In this trial, participants will receive an open-label combination of benralizumab and AirSupra, which may help maintain better asthma control.⁶⁷⁸⁹¹⁰